Last edition
News about "GlycoNex "
GlycoNex Signs Manufacturing Deal with Sterling for GNX102-ADC Clinical Trial Production
GNX102-ADC combines GlycoNex's proprietary monoclonal antibody (mAb), GNX102, and cytotoxic drug therapies to elicit cellular cytotoxicity to target cancer cells with high specificity.
GlycoNex | 13/11/2024 | By Aishwarya | 109
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members